Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Prescribing

Department of Health reports 5.2% growth in spending on branded drugs

NHS spending on branded drugs made available under the Pharmaceutical Price Regulation Scheme (PPRS) between 2013 and 2014 went up by 5.2%, according to the Department of Health (DH). In the image, a shelf of branded drugs in a pharmacy dispensary

Source: eye35 / Alamy Stock Photo

The rise in NHS spending on branded drugs occurred mostly in the hospital sector

NHS spending on branded drugs made available under the Pharmaceutical Price Regulation Scheme (PPRS) between 2013 and 2014 went up by 5.2%, according to an analysis published by the Department of Health on 7 September 2015.

Other figures, supplied by IMS Health and used in the analysis, estimated a higher increase of 8.2%. The rise, according to the document, occurred mostly in the hospital sector where the use of branded drugs went up by 16.5% between 2013 and 2014. Community sector spend increased by 1.9% over the same period.

Most of the rise in spending on branded drugs occurred in products for the treatment of breast and advanced prostate cancer, drugs for rheumatoid arthritis and Crohn’s disease and for wet age-related macular degeneration (ADM) and new oral anticoagulants.

Aflibercept (Eylea) for the treatment of wet AMD had the largest increase in spending in the 12 months analysed, rising by £102m, according to the report.

On its website, the Department of Health explains the difference between the PPRS figures and the IMS Health data: “IMS Health data, which provides product level data across the specified period, has been used to compare the growth in branded medicines.

“PPRS data and IMS Health data are not directly comparable due to differences in definitions and price bases — however, the IMS Health data gives a good indication of the reasons behind the growth.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069346

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • NHS spending on branded drugs made available under the Pharmaceutical Price Regulation Scheme (PPRS) between 2013 and 2014 went up by 5.2%, according to the Department of Health (DH). In the image, a shelf of branded drugs in a pharmacy dispensary

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.